Leading investments into growth-stage technology and healthcare companies, William Staveacre brings operating and board experience to capital allocation decisions. He evaluates revenue model durability, unit economics, and founder-market fit to prioritize deals that can scale to exit via trade sale or IPO. Active in LP fundraising and syndicate formation, he contributes to portfolio governance and go-to-market execution. Prior roles encompass operating management and investment leadership, providing cross-functional insight into product, sales and financial operations.
Leading investments into growth-stage technology and healthcare companies, William Staveacre brings operating and board experience to capital allocation decisions. He evaluates revenue model durability, unit economics, and founder-market fit to prioritize deals that can scale to exit via trade sale or IPO. Active in LP fundraising and syndicate formation, he contributes to portfolio governance and go-to-market execution. Prior roles encompass operating management and investment leadership, providing cross-functional insight into product, sales and financial operations.
Focuses on growth-stage technology and healthcare companies, prioritizing repeatable revenue models, strong unit economics and clear founder-market fit. Allocates capital with a staged, milestone-driven approach that balances runway extension and go-to-market scaling, targeting exits via trade sale or IPO over a 3–7 year horizon. Employs active board engagement and operating partnership to de-risk commercial execution, leaning toward B2B SaaS, digital health and platform-enabled services. Investment decisions emphasize differentiated product defensibility, measurable growth efficiency and founder alignment; downside risk is managed through conviction-weighted positions and syndicate co-investment.
Focuses on growth-stage technology and healthcare companies, prioritizing repeatable revenue models, strong unit economics and clear founder-market fit. Allocates capital with a staged, milestone-driven approach that balances runway extension and go-to-market scaling, targeting exits via trade sale or IPO over a 3–7 year horizon. Employs active board engagement and operating partnership to de-risk commercial execution, leaning toward B2B SaaS, digital health and platform-enabled services. Investment decisions emphasize differentiated product defensibility, measurable growth efficiency and founder alignment; downside risk is managed through conviction-weighted positions and syndicate co-investment.
| Trades 7995 | Longs Won 3759/7995 47% | Profit Factor 1.38 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $241,058.44 |
| Average Win $49,010.21 | Best Trade (Sep 01) $7.08M | Sharpe Ratio -40.44 |
| Average Loss -$31,504.48 | Worst Trade (Aug 26) -$16.31M | Z-Score -0.11 (8.53%) |
| Commissions $0 | Avg. Trade Length 4m 1w 6d | Expectancy $6,351.02 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 17,544 | 15,789 | 14,035 | 12,281 | 10,526 | 8,772 | 7,018 | 5,263 | 3,509 | 1,754 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 8787 87877F103 | 81 | $6,266 | $6,266 | - | - | - | 0.0 |
A Agilent Technologies Inc. | 3,218 | $422,617.72 | $477,036.32 | - | $54,418.6 | 12.88% | 0.0 |
ABCB Ameris Bancorp | 151 | $13,629.26 | $13,374.07 | - | -$255.19 | -1.87% | 0.0 |
ACEL Accel Entertainment Inc. | 113 | $1,232.83 | $1,394.42 | - | $161.59 | 13.11% | 0.0 |
ACHV Achieve Life Sciences Inc. | 60,514 | $395,156.42 | $438,726.5 | - | $43,570.08 | 11.03% | +8.371% |
ACI Albertsons Companies, Inc. | 8,285 | $112,096.05 | $99,502.85 | - | -$12,593.2 | -11.23% | 0.0 |
ACVA ACV Auctions Inc. | 834 | $3,536.16 | $6,471.84 | - | $2,935.68 | 83.02% | 0.0 |
ADBE Adobe Inc. | 1,871 | $542,654.44 | $484,121.25 | - | -$58,533.19 | -10.79% | 0.0 |
ADI Analog Devices, Inc. | 3,046 | $986,045.89 | $1.17M | - | $184,927.89 | 18.75% | 0.0 |
ADMA Adma Biologics Inc. | 266 | $2,396.66 | $2,601.48 | - | $204.82 | 8.55% | 0.0 |
ADNT Adient plc | 222 | $4,080.36 | $4,446.66 | - | $366.3 | 8.98% | +7.573% |
ADSK Autodesk, Inc. | 2,750 | $535,599.58 | $686,152.5 | - | $150,552.92 | 28.11% | 0.0 |
ADT ADT Inc. | 9,379 | $61,526.24 | $68,560.49 | - | $7,034.25 | 11.43% | 0.0 |
AEE Ameren Corporation | 212 | $23,964.48 | $23,069.84 | - | -$894.64 | -3.73% | 0.0 |
AESI Atlas Energy Solutions Inc. | 9,453 | $157,724.71 | $110,978.22 | - | -$46,746.49 | -29.64% | 0.0 |
AFL Aflac Inc. | 43,670 | $5.12M | $5.27M | - | $155,538.33 | 3.04% | 0.0 |
AGEN Agenus Inc. | 27,669 | $87,157.35 | $190,916.1 | - | $103,758.75 | 119.05% | 0.0 |
AGM Federal Agricultural Mortgage Corporation | 20 | $3,886 | $4,761 | - | $875 | 22.52% | 0.0 |
AGO Assured Guaranty Ltd. | 1,968 | $157,754.88 | $147,127.68 | - | -$10,627.2 | -6.74% | 0.0 |
AGYS Agilysys Inc. | 256 | $26,470.4 | $27,481.6 | - | $1,011.2 | 3.82% | 0.0 |